{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:24:52Z","timestamp":1789604692731,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2022J02034"],"award-info":[{"award-number":["2022J02034"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Joint Funds for the Innovation of Science and Technology of Fujian Province","award":["2019Y9119"],"award-info":[{"award-number":["2019Y9119"]}]},{"DOI":"10.13039\/501100017686","name":"Fujian Provincial Health Technology Project","doi-asserted-by":"publisher","award":["2020CXA037"],"award-info":[{"award-number":["2020CXA037"]}],"id":[{"id":"10.13039\/501100017686","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fujian Provincial Finance Project","award":["No.BPB-2022LJB"],"award-info":[{"award-number":["No.BPB-2022LJB"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Primary focal hyperhidrosis (PFH) may be attributed to the up-regulation of the cholinergic receptor nicotinic alpha 1 subunit (CHRNA1) in eccrine glands. Plasminogen activator inhibitor-1 (PAI1, encoded by <jats:italic>SERPINE1<\/jats:italic>) is reported to inhibit the expression of CHRNA1, while the role of PAI1 in hyperhidrosis is unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p><jats:italic>Serpine1<\/jats:italic> KO mice, <jats:italic>Serpine1<\/jats:italic>-Tg mice, and wild type BALB\/c mice were intraperitoneally injected with pilocarpine hydrochloride to induce PFH. Cisatracurium (CIS, antagonist of CHRNA1) or PAI-039 (small-molecule inhibitor of PAI1) was pre-administrated before the induction of hyperhidrosis. On the other hand, <jats:italic>Chrna1<\/jats:italic>-expressing AAV was constructed and administered to <jats:italic>Serpine1<\/jats:italic>-Tg mice with hydrochloride stimulation. Hydrochloride-related biomarkers, such as acetylcholine (ACH) in the serum, calcium voltage-gated channel subunit alpha1 C (CACNA1C), and aquaporin 5 (AQP5) in sweat glands of mice were assayed with ELISA, RT-PCR, and Western blot.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The administration of PAI-039 or <jats:italic>Pai1<\/jats:italic> knock-out increased <jats:italic>Chrna1<\/jats:italic> expression, sweat secretion, and hydrochloride-related biomarkers (ACH, CACNA1C, and AQP5) expression. On the other hand, CIS administration diminished the strengthened hyperhidrosis phenotype induced by <jats:italic>Pai1<\/jats:italic> knock-out with decreased sweat gland secretion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>PAI1 inhibits CHRNA1-mediated hydrochloride-induced hyperhidrosis, with decreased sweat gland secretion and diminished ACH, AQP5, and CACNA1C expression. These results indicate the potential to utilize PAI1 to alleviate PFH.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-023-02808-0","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T14:03:47Z","timestamp":1691157827000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["PAI1 inhibits the pathogenesis of primary focal hyperhidrosis by targeting CHRNA1"],"prefix":"10.1186","volume":"18","author":[{"given":"Jian-Feng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7484-6143","authenticated-orcid":false,"given":"Jian-Bo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"2808_CR1","doi-asserted-by":"publisher","unstructured":"Khurana RK. Sweating Disorders; in (Aminoff MJ, and Daroff RB, eds) Encyclopedia of the Neurological Sciences (Second Edition). Oxford, Academic Press, 2014, vol. https:\/\/doi.org\/10.1016\/B978-0-12-385157-4.00513-3p.^pp. 359\u2013362.","DOI":"10.1016\/B978-0-12-385157-4.00513-3"},{"key":"2808_CR2","first-page":"523","volume":"20","author":"V Liu","year":"2021","unstructured":"Liu V, Farshchian M, Potts GA. Management of primary focal hyperhidrosis: an Algorithmic Approach. J Drugs Dermatol. 2021;20:523\u20138.","journal-title":"J Drugs Dermatol"},{"key":"2808_CR3","doi-asserted-by":"publisher","unstructured":"Owens AP, Low DA, Iodice V, et al. Emotion and the autonomic nervous System\u2014A Two-Way Street: insights from affective, autonomic and dissociative Disorders; in Reference Module in Neuroscience and Biobehavioral psychology. Elsevier; 2017. https:\/\/doi.org\/10.1016\/B978-0-12-809324-5.01799-5p.^pp.","DOI":"10.1016\/B978-0-12-809324-5.01799-5"},{"key":"2808_CR4","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10286-021-00794-6","volume":"31","author":"MAS Henning","year":"2021","unstructured":"Henning MAS, Thorlacius L, Ibler KS, et al. How to diagnose and measure primary hyperhidrosis: a systematic review of the literature. Clin Auton Res. 2021;31:511\u201328.","journal-title":"Clin Auton Res"},{"key":"2808_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s43159-021-00092-w","volume":"17","author":"IE Elhalaby","year":"2021","unstructured":"Elhalaby IE, Mansour MA, Tawfik AMI, et al. Thoracoscopic T2-T3 versus T4 sympathectomy for primary palmar hyperhidrosis in children and adolescents: a randomized comparative study. Annals of Pediatric Surgery. 2021;17:26.","journal-title":"Annals of Pediatric Surgery"},{"key":"2808_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s43159-020-00031-1","volume":"16","author":"MS Mostafa","year":"2020","unstructured":"Mostafa MS, Elsherbeny M, Abdelbarr A, et al. Thoracoscopic excision versus radiofrequency ablation of the sympathetic chain as a treatment for palmar hyperhidrosis: comparative study. Annals of Pediatric Surgery. 2020;16:21.","journal-title":"Annals of Pediatric Surgery"},{"key":"2808_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.athoracsur.2012.10.068","volume":"95","author":"NB de Moura J\u00fanior","year":"2013","unstructured":"de Moura J\u00fanior NB, das-Neves-Pereira JC, de Oliveira FR, et al. Expression of acetylcholine and its receptor in human sympathetic ganglia in primary hyperhidrosis. Ann Thorac Surg. 2013;95:465\u201370.","journal-title":"Ann Thorac Surg"},{"key":"2808_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1152\/jn.01038.2015","volume":"116","author":"I Roux","year":"2016","unstructured":"Roux I, Wu JS, McIntosh JM, et al. Assessment of the expression and role of the \u03b11-nAChR subunit in efferent cholinergic function during the development of the mammalian cochlea. J Neurophysiol. 2016;116:479\u201392.","journal-title":"J Neurophysiol"},{"key":"2808_CR9","doi-asserted-by":"publisher","first-page":"103598","DOI":"10.1016\/j.mcn.2021.103598","volume":"111","author":"JB Lin","year":"2021","unstructured":"Lin JB, Kang MQ, Huang LP, et al. CHRNA1 promotes the pathogenesis of primary focal hyperhidrosis. Mol Cell Neurosci. 2021;111:103598.","journal-title":"Mol Cell Neurosci"},{"key":"2808_CR10","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/acn3.51558","volume":"9","author":"JB Lin","year":"2022","unstructured":"Lin JB, Lin NL, Li X, et al. Antagonist of Chrna1 prevents the pathogenesis of primary focal hyperhidrosis. Ann Clin Transl Neurol. 2022;9:786\u201394.","journal-title":"Ann Clin Transl Neurol"},{"key":"2808_CR11","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.bbrc.2020.10.089","volume":"534","author":"A Aihemaiti","year":"2021","unstructured":"Aihemaiti A, Yamamoto N, Piao J, et al. A novel PAI-1 inhibitor prevents ageing-related muscle fiber atrophy. Biochem Biophys Res Commun. 2021;534:849\u201356.","journal-title":"Biochem Biophys Res Commun"},{"key":"2808_CR12","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41598-020-79948-x","volume":"11","author":"JA Levine","year":"2021","unstructured":"Levine JA, Oleaga C, Eren M, et al. Role of PAI-1 in hepatic steatosis and dyslipidemia. Sci Rep. 2021;11:430.","journal-title":"Sci Rep"},{"key":"2808_CR13","doi-asserted-by":"publisher","unstructured":"Chandler WL. Chap. 146 - Laboratory Techniques in Fibrinolysis Testing; in (Shaz BH, Hillyer CD, and Reyes Gil M, eds) Transfusion Medicine and Hemostasis (Third Edition). Elsevier, 2019, vol. https:\/\/doi.org\/10.1016\/B978-0-12-813726-0.00146-Xp.^pp. 865\u2013868.","DOI":"10.1016\/B978-0-12-813726-0.00146-X"},{"key":"2808_CR14","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1172\/JCI116892","volume":"92","author":"P Carmeliet","year":"1993","unstructured":"Carmeliet P, Kieckens L, Schoonjans L, et al. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest. 1993;92:2746\u201355.","journal-title":"J Clin Invest"},{"key":"2808_CR15","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1080\/15548627.2017.1375633","volume":"13","author":"A Du","year":"2017","unstructured":"Du A, Huang S, Zhao X, et al. Suppression of CHRN endocytosis by carbonic anhydrase CAR3 in the pathogenesis of myasthenia gravis. Autophagy. 2017;13:1981\u201394.","journal-title":"Autophagy"},{"key":"2808_CR16","doi-asserted-by":"publisher","first-page":"e1007857","DOI":"10.1371\/journal.pgen.1007857","volume":"15","author":"Y Liu","year":"2019","unstructured":"Liu Y, Sugiura Y, Chen F, et al. Blocking skeletal muscle DHPRs\/Ryr1 prevents neuromuscular synapse loss in mutant mice deficient in type III neuregulin 1 (CRD-Nrg1). PLoS Genet. 2019;15:e1007857.","journal-title":"PLoS Genet"},{"key":"2808_CR17","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1016\/j.jid.2021.03.030","volume":"141","author":"YJ Tseng","year":"2021","unstructured":"Tseng YJ, Lee CH, Chen WY, et al. Inhibition of PAI-1 Blocks PD-L1 endocytosis and improves the response of Melanoma cells to Immune Checkpoint Blockade. J Invest Dermatol. 2021;141:2690\u20132698e2696.","journal-title":"J Invest Dermatol"},{"key":"2808_CR18","doi-asserted-by":"publisher","first-page":"562481","DOI":"10.1155\/2011\/562481","volume":"2011","author":"R-P Czekay","year":"2011","unstructured":"Czekay R-P, Wilkins-Port CE, Higgins SP, et al. PAI-1: an integrator of Cell Signaling and Migration. Int J Cell Biol. 2011;2011:562481.","journal-title":"Int J Cell Biol"},{"key":"2808_CR19","first-page":"782829","volume":"12","author":"CS Moon","year":"2022","unstructured":"Moon CS, Moon D, Kang SK. Aquaporins in Cancer Biology Front Oncol. 2022;12:782829.","journal-title":"Aquaporins in Cancer Biology Front Oncol"},{"key":"2808_CR20","doi-asserted-by":"crossref","unstructured":"Piraino LR, Benoit DSW, DeLouise LA. Salivary gland tissue Engineering Approaches: state of the art and future directions. Cells. 2021;10.","DOI":"10.3390\/cells10071723"},{"key":"2808_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1113\/jphysiol.2001.020180","volume":"541","author":"Y Song","year":"2002","unstructured":"Song Y, Sonawane N, Verkman AS. Localization of aquaporin-5 in sweat glands and functional analysis using knockout mice. J Physiol. 2002;541:561\u20138.","journal-title":"J Physiol"},{"key":"2808_CR22","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/schbul\/sby096","volume":"44","author":"AL Moon","year":"2018","unstructured":"Moon AL, Haan N, Wilkinson LS, et al. CACNA1C: Association with Psychiatric Disorders, Behavior, and neurogenesis. Schizophr Bull. 2018;44:958\u201365.","journal-title":"Schizophr Bull"},{"key":"2808_CR23","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1038\/s41380-022-01523-9","volume":"27","author":"M Li","year":"2022","unstructured":"Li M, Li T, Xiao X, et al. Phenotypes, mechanisms and therapeutics: insights from bipolar disorder GWAS findings. Mol Psychiatry. 2022;27:2927\u201339.","journal-title":"Mol Psychiatry"},{"key":"2808_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/B978-0-12-385083-6.00029-2","volume-title":"Nutritional and therapeutic interventions for diabetes and metabolic syndrome","author":"K Miyashita","year":"2012","unstructured":"Miyashita K, Nishikawa S, Hosokawa M. Chap. 29 - therapeutic effect of Fucoxanthin on metabolic syndrome and type 2 diabetes. In: Bagchi D, Sreejayan N, editors. Nutritional and therapeutic interventions for diabetes and metabolic syndrome. San Diego: Academic Press; 2012. pp. 367-79. https:\/\/doi.org\/10.1016\/B978-0-12-385083-6.00029-2"},{"key":"2808_CR25","doi-asserted-by":"crossref","unstructured":"Ismail AA, Shaker BT, Bajou K. The plasminogen-activator plasmin system in physiological and pathophysiological angiogenesis. Int J Mol Sci. 2021;23.","DOI":"10.3390\/ijms23010337"},{"key":"2808_CR26","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2174\/138945007781662346","volume":"8","author":"PA Andreasen","year":"2007","unstructured":"Andreasen PA. PAI-1 - a potential therapeutic target in cancer. Curr Drug Targets. 2007;8:1030\u201341.","journal-title":"Curr Drug Targets"},{"key":"2808_CR27","doi-asserted-by":"crossref","unstructured":"Mahmood N, Rabbani SA. Fibrinolytic system and Cancer: diagnostic and therapeutic applications. Int J Mol Sci. 2021;22.","DOI":"10.3390\/ijms22094358"},{"key":"2808_CR28","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1161\/STROKEAHA.111.622217","volume":"43","author":"A Tj\u00e4rnlund-Wolf","year":"2012","unstructured":"Tj\u00e4rnlund-Wolf A, Brogren H, Lo EH, et al. Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases. Stroke. 2012;43:2833\u20139.","journal-title":"Stroke"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02808-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02808-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02808-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T16:41:14Z","timestamp":1700325674000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02808-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2808"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02808-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"assertion":[{"value":"7 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures were approved by the Animal Ethics Committee of Fujian Medical University (2020[328]). This study was performed in strict accordance with the NIH guidelines for the care and use of laboratory animals (8th edition, NIH).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"205"}}